YCC Entrepreneurs
Over the past 20 years, Yale inventions have led to the creation of nearly 60 companies in the New Haven region that have attracted more than $1 billion of professional venture capital investment and have created over 1,400 jobs in the region. Many of these local companies are focused on oncology drug development based on science from Yale Cancer Center members, including:
Research Program: Developmental Therapeutics
Arvinas is a pharmaceutical company focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases.
Research Program: Radiobiology & Radiotherapy
Research Program: Radiobiology & Radiotherapy
Cybrexa Therapeutics is an oncology-focused biotechnology company developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment.
Research Program: Developmental Therapeutics
Immunova Pharmaceuticals has a proprietary Nanolipogel™ platform to deliver desired combinations of drugs in nanoparticle formulations to the disease microenvironment.
Research Program: Cancer Signaling Networks
IsoPlexis is transforming precision oncology in cell and cancer immunotherapy by defining the complete function of each cell for the first time.
Research Program: Developmental Therapeutics
Kleo Pharmaceuticals is pioneering a new class of immunotherapies utilizing small molecules to activate an individual’s own immune system to fight against cancers and infectious diseases.
Research Program: Cancer Signaling Networks
Celldex Therapeutics acquired Kolltan Pharmaceuticals. Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate.
Research Program: Developmental Therapeutics
Modulate Therapeutics is a special purpose company created to develop one compound, IMM-01, to proof-of-concept.
Research Program: Cancer Signaling Networks
Navigate (formally HistoRx) is developing novel diagnostic solutions to help turn innovative cancer treatment ideas into reality.
Research Program: Cancer Immunology
NextCure is focused on discovering and developing next generation immunotherapy-based biologics for cancer and other immune-related disorders.
Research Program: Developmental Therapeutics
Proteolix/Acquired by Onyx Pharma and develops and markets medicines for the treatment of cancer.
Research Program: Developmental Therapeutics
Osmol Therapeutics is developing a therapy for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) and Neurologic Impairment.
Research Program: Radiobiology & Radiotherapy
Research Program: Radiobiology & Radiotherapy
Nucleus Therapeutics/Acquired by Patrys is focused on the development of antibody therapies for major market opportunities in the oncology area.
Research Program: Developmental Therapeutics
pHILiP Inc. is focused on detecting, targeting, and treating acidic diseased tissue using selective insertion and folding of membrane peptides, primarily in oncology.
Research Program: Developmental Therapeutics
PhytoCeutica develops herbal therapeutics for cancer and was acquired by Kadmon Pharmaceuticals.
Research Program: Cancer Immunology
Simcha Therapeutics in New Haven is developing potential therapies based on experiments from the Yale lab of Dr. Aaron Ring.
Research Program: Cancer Microbiology
Omnis Pharmaceuticals- merged to form Vyriad and is a clinical stage biotechnology company dedicated to delivering groundbreaking virus-based therapies for cancer patients.
Research Program: Cancer Immunology
Vedanta Biosciences is using its proprietary platform to discover and develop a novel class of drugs that modulate pathways of interaction between the human microbiome and the host immune system to treat disease.
Research Program: Developmental Therapeutics
Yiviva is a biotechnology company to develop evidence-based botanical products to address aging-associated diseases.